Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Cyclerion Therapeutics, Inc. (CYCN) had Return on Equity of -111.56% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-5.26M |
|
-- |
|
-- |
|
$12.95M |
|
$-12.95M |
|
$0.36M |
|
$-12.59M |
|
$-12.59M |
|
$-12.59M |
|
$-12.59M |
|
$-5.26M |
|
$-12.59M |
|
$-12.95M |
|
$-12.95M |
|
2.34M |
|
2.34M |
|
$-2.25 |
|
$-2.25 |
|
| Balance Sheet Financials | |
$8.02M |
|
-- |
|
$5.35M |
|
$13.37M |
|
$2.09M |
|
-- |
|
-- |
|
$2.09M |
|
$11.29M |
|
$11.29M |
|
$11.29M |
|
2.47M |
|
| Cash Flow Statement Financials | |
$-21.25M |
|
$10.40M |
|
$5.02M |
|
$13.38M |
|
$7.57M |
|
$-5.81M |
|
$1.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-21.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-111.56% |
-111.56% |
|
-94.16% |
|
-111.56% |
|
$4.56 |
|
$-9.09 |
|
$-9.09 |
|